【摘要】 目的:观察不同剂量的阿托伐他汀对急性冠脉综合征(ACS)患者PCI围手术期的炎症因子及血清黏附因子影响。方法:将入选的120例ACS患者随机分为治疗组和对照组,每组60例,治疗组给予阿托伐他汀40mg/d,对照组给予阿托伐他汀20mg/d,自术前至术后1个月。于PCI术前及术后1周、2周测血浆hs-CRP,及血浆可溶性细胞间黏附分子(soluble intercellular adhesionmolecuh-1,sICAM-1)、血管细胞黏附分子(soluble vascular cell adhesion molecule-1,sVCAM-1)。结果:两组术后1周hs-CRP均明显升高(P<0.01),但对照组较治疗组明显升高(P<0.01),经治疗后2周两组hs-CRP较术前均降低(P<0.01),治疗组降低更为显著(P<0.01)。治疗组在PCI术后第7d,两种血清黏附分子水平显著低于对照组(P<0.01)。结论:较大剂量阿托伐他汀能够抑制PIC术后炎症反应,显著降低sICAM-1、sVCAM-1水平,进而减少PCI术后不良事件的发生。更多还原

【Abstract】 OBJECTIVE:To explore the influence of different doses of atorvastatin on adhesion molecule and inflammatory cytokines levels in patients with acute coronary syndrome(ACS) after receiving percutaneous coronary intervention(PCI).METHODS;120 ACS patients were randomly divided into treatment group(n =60) and control group(n =60).The treatment group received atorvastatin(40mg/d) and the control group received atorvastatin(20mg/d) from the preoperative to postoperative months.Plasma hs-CRP,plasma soluble intercellular adhesion molecule(sICAM-1) and vascular cell adhesion molecule(sVCAM-1) were measured before PCI and subsequently after PCI for one week and two weeks.RESULTS:hs-CRP were significantly higher(P <0.01) in the first week after PCI,but the treatment group was significantly higher than those in the control group(P <0.01).hsCRP lelves were all decreased in two groups in two weeks after treatment(P <0.01) and the treatment group were significantly lower(P <0.01).In treatment group in the first seven days after PCI two kinds of adhesion molecules in the serum levels were significantly lower than those in control group(P < 0.01).CONCLUSION:Larger dose of atorvastatin can inhibit inflammation after PCI and significantly reduce sICAM-1 and sVCAM-1 levels and reduce the occurrence of adverse events after PCI.更多还原